Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma

References

• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention [online]. 2015 [cited 2015 Dec 7]. Available from: http://www.ginasthma.com
   Google Scholar
• Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11:404–406.
   PubMedGoogle Scholar
• Scichilone N, Contino A, Figlioli GB, et al. Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options. Patient Prefer Adherence. 2010;4:17–23.
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010;4:CD005533.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bantje TA, João Gomes M, et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med. 2003;2:275–281.
   PubMedGoogle Scholar
• Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J. 2007;29:587–595.
   PubMed Web of Science ®Google Scholar
• Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest. 2003;123:1480–1487.
   PubMed Web of Science ®Google Scholar
• Ringdal N, Eliraz A, Pruzinec R, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med. 2003;97:234–241.
   PubMed Web of Science ®Google Scholar
• Tal A, Simon G, Vermeulen JH, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol. 2002;34:342–350.
   PubMed Web of Science ®Google Scholar
• Huchon G, Magnussen H, Chuchalin A, et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med. 2009;103:41–49.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112:29–36.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Nicolini G, Olivieri D, et al. Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother. 2008;9:479–490.
   PubMed Web of Science ®Google Scholar
• Marceau C, Lemière C, Berbiche D, et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol. 2006;118:574–581.
   PubMed Web of Science ®Google Scholar
• Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2:63–72.
   PubMedGoogle Scholar
• Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:245–251.
   PubMed Web of Science ®Google Scholar
• Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med. 2005;99:1263–1267.
   PubMed Web of Science ®Google Scholar
• Tamm M, Richards DH, Beghé B, et al. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med. 2012;106(Suppl 1):S9–S19.
   PubMedGoogle Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002;19:182–191.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med. 2003;139:359–370.
   PubMed Web of Science ®Google Scholar
• Horvath G, Mendes ES, Schmid N, et al. The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. J Allergy Clin Immunol. 2007;120:1103–1109.
   PubMed Web of Science ®Google Scholar
• Giembycz MA, Kaur M, Leigh R, et al. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol. 2008;153:1090–1104.
   PubMed Web of Science ®Google Scholar
• Bjermer L. The role of small airway disease in asthma. Curr Opin Pulm Med. 2014;20:23–30.
   PubMed Web of Science ®Google Scholar
• Alfieri V, Aiello M, Pisi R, et al. Small airway dysfunction is associated to excessive bronchoconstriction in asthmatic patients. Respir Res. 2014;15:86.
   PubMed Web of Science ®Google Scholar
• Theophilus A, Moore A, Prime D, et al. Co-deposition of salmeterol and fluticasone propionate by a combination inhaler. Int J Pharm. 2006;313:14–22.
   PubMed Web of Science ®Google Scholar
• Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001;5:1–149.
   PubMedGoogle Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335–371.
   PubMed Web of Science ®Google Scholar
• Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ. 2001;323:896–900.
   PubMed Web of Science ®Google Scholar
• Lavorini F. The challenge of delivering therapeutic aerosols to asthma patients. ISRN Allergy. 2013;2013:1–17.
   Google Scholar
• Laube BL, Janssens HM, De Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308–1331.
   PubMed Web of Science ®Google Scholar
• Hamid Q. Pathogenesis of small airways in asthma. Respiration. 2012;84:4–11.
   PubMed Web of Science ®Google Scholar
• van den Berge M, ten Hacken NH, Cohen J, et al. Small airway disease in asthma and COPD: clinical implications. Chest. 2011;139:412–423.
   PubMed Web of Science ®Google Scholar
• Scichilone N, Battaglia S, Sorino C, et al. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy. 2010;65:897–902.
   PubMed Web of Science ®Google Scholar
• Vos W, De Backer J, Poli G, et al. Novel functional imaging of changes in small airways of patients treated with extrafine beclomethasone/Formoterol. Respiration. 2013;86:393–401.
   PubMed Web of Science ®Google Scholar
• De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23:137–148.
   PubMed Web of Science ®Google Scholar
• Müller V, Gálffy G, Eszes N, et al. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation. BMC Pulm Med. 2011 Jul 15;11:40.
   PubMed Web of Science ®Google Scholar
• Scichilone N, Spatafora M, Battaglia S, et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. J Asthma Allergy. 2013;6:11–21.
   PubMedGoogle Scholar
• Adcock IM, Gilbey T, Gelder CM, et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med. 1996;154:771–782.
   PubMed Web of Science ®Google Scholar
• Chong LK, Peachell PT. Beta-adrenoceptor reserve in human lung: a comparison between airway smooth muscle and mast cells. Eur J Pharmacol. 1999;378:115–122.
   PubMed Web of Science ®Google Scholar
• Leach CL, Kuehl PJ, Chand R, et al. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol. 2012;108:195–200.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Keating GM. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs. 2006;66:1475–1483discussion 84-5
   PubMed Web of Science ®Google Scholar
• Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol. 2000;106:1209–1226.
   PubMed Web of Science ®Google Scholar
• Mariotti F, Sergio F, Acerbi D, et al. Lung deposition of the extra-fine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients. Presented at the European Respiratory Society 21st Annual Congress; 2011 Sep 24–28; Amsterdam, The Netherlands.
   Google Scholar
• Corradi M, Chrystyn H, Cosio BG, et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv. 2014;11:1497–1506.
   PubMed Web of Science ®Google Scholar
• Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther. 2007;20:290–303.
   PubMed Web of Science ®Google Scholar
• Pasquali I, Merusi C, Brambilla G, et al. Optical diagnostics study of air flow and powder fluidisation in Nexthaler®-Part I: studies with lactose placebo formulation. Int J Pharm. 2015 Nov 3;496:780–791. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Voshaar T, Spinola M, Linnane P, et al. Comparing usability of NEXThaler® with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients. J Aerosol Med Pulm Drug Deliv. 2014;27:363–370.
   PubMed Web of Science ®Google Scholar
• Kanniess F, Scuri M, Vezzoli S, et al. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler®) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: a randomised, double-blind trial. Pulm Pharmacol Ther. 2015;30:121–127.
   PubMed Web of Science ®Google Scholar
• Scuri M, Alfieri V, Giorgio A, et al. Measurement of the inhalation profile through a novel dry powder inhaler (NEXThaler®) in asthmatic patients using acoustic monitoring. Am J Respir Crit Care Med. 2013;187:A1931.
   Web of Science ®Google Scholar
• Nicolini G, Chetta A, Simonazzi A, et al. Both bronchial and alveolar exhaled nitric oxide are reduced with extrafine beclomethasone dipropionate in asthma. Allergy Asthma Proc. 2010;31:85–90.
   PubMed Web of Science ®Google Scholar
• O’Connor BJ, Collarini S, Poli G, et al. Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial. BMC Pulm Med. 2011;11:60.
   PubMed Web of Science ®Google Scholar
• Popov TA, Petrova D, Kralimarkova TZ, et al. Real life clinical study design supporting the effectiveness of extra-fine inhaled beclomethasone/formoterol at the level of small airways of asthmatics. Pulm Pharmacol Ther. 2013;26:624–629.
   PubMed Web of Science ®Google Scholar
• Kirsten AM, Watz H, Brindicci C, et al. Effects of beclomethason/formoterol and budesonide/formoterol fixed combinations on lung function and airway inflammation in patients with mild to moderate asthma -an exploratory study. Pulm Pharmacol Ther. 2015;31:79–84.
   PubMed Web of Science ®Google Scholar
• Papi A, Paggiaro PL, Nicolini G, et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007;29:682–689.
   PubMed Web of Science ®Google Scholar
• Papi A, Paggiaro PL, Nicolini G, et al. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007;62:1182–1188.
   PubMed Web of Science ®Google Scholar
• Allegra L, Cremonesi G, Girbino G, et al. PRISMA (PRospectIve Study on asthMA control) Study Group. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med. 2012;106:205–214.
   PubMed Web of Science ®Google Scholar
• Terzano C, Cremonesi G, Girbino G, et al. (PRospectIve Study on asthMA control) Study Group. 1-year prospective real life monitoring of asthma control and quality of life in Italy. Respir Res. 2012;13:112.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Peché R, Van Den Brande P, et al. Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status. Respir Med. 2012;106:811–819.
   PubMed Web of Science ®Google Scholar
• Singh D, Corradi M, Bindi E, et al. Relief of methacholine-induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in comparison with salbutamol in asthma. Pulm Pharmacol Ther. 2012;25:392–398.
   PubMed Web of Science ®Google Scholar
• Humbert M, Andersson TL, Buhl R. Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma. Allergy. 2008;63:1567–1580.
   PubMed Web of Science ®Google Scholar
• Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013 Mar;1(1):23–31.
   PubMed Web of Science ®Google Scholar
• Singh D, Piccinno A, Borrill Z, et al.Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterolcombination inhaler in asthmatic patients. Pulm Pharmacol Ther. 2008;21:551–557.
   PubMed Web of Science ®Google Scholar